2026 FDA TRT Label Update: What the Prostate Cancer Change Means
What Changed for Tetsosterone? On June 18, 2026, the FDA and HHS requested significant updates to testosterone replacement therapy (TRT) prescribing labels. The most notable change: narrowing the prostate cancer warning from a broad caution against "known or suspected" prostate cancer to a contraindication specifically for metastatic prostate cancer. The agencies also requested removing a 2015 limitation on age-related hypogonadism and easing warnings tied to benign prostatic hyperplasia (BPH). These are requested changes, not yet finalized labels — but they reflect where the evidence has been pointing for years. Why This Matters to Patients If you've avoided asking about TRT because of the prostate cancer warning on the package insert, this update speaks directly to that hesitation. It doesn't mean TRT is risk-free or right for everyone — it means the federal government's own review of the evidence no longer supports the older, broader warning language. Bac...
